Atea Pharmaceuticals, Inc. (AVIR)
AVIR Stock Price Chart
Explore Atea Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AVIR price movements and trends.
AVIR Company Profile
Discover essential business fundamentals and corporate details for Atea Pharmaceuticals, Inc. (AVIR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Oct 2020
Employees
55.00
Website
https://www.ateapharma.comCEO
Jean-Pierre Sommadossi
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Financial Timeline
Browse a chronological timeline of Atea Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.56, while revenue estimate is $33.03m.
Earnings released on 12 May 2026
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.00%.
Earnings released on 5 Mar 2026
EPS came in at -$0.57 falling short of the estimated -$0.49 by -16.33%.
Earnings released on 12 Nov 2025
EPS came in at -$0.53 falling short of the estimated -$0.46 by -15.22%.
Earnings released on 7 Aug 2025
EPS came in at -$0.44 surpassing the estimated -$0.46 by +4.35%.
Earnings released on 12 May 2025
EPS came in at -$0.40 surpassing the estimated -$0.56 by +28.57%.
Earnings released on 6 Mar 2025
EPS came in at -$0.40 falling short of the estimated -$0.35 by -14.29%.
Earnings released on 7 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.49 by +24.49%.
Earnings released on 7 Aug 2024
EPS came in at -$0.48 surpassing the estimated -$0.76 by +36.84%.
Earnings released on 14 May 2024
EPS came in at -$0.75 falling short of the estimated -$0.61 by -22.95%.
Earnings released on 28 Feb 2024
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%.
Earnings released on 8 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.48 by +16.67%.
Earnings released on 8 Aug 2023
EPS came in at -$0.34 surpassing the estimated -$0.47 by +27.66%.
Earnings released on 8 May 2023
EPS came in at -$0.43 surpassing the estimated -$0.48 by +10.42%.
Earnings released on 28 Feb 2023
EPS came in at -$0.41 surpassing the estimated -$0.45 by +8.89%.
Earnings released on 7 Nov 2022
EPS came in at -$0.10 surpassing the estimated -$0.44 by +77.27%.
Earnings released on 8 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.52 by +26.92%.
Earnings released on 10 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.58 by +12.07%.
Earnings released on 28 Feb 2022
EPS came in at $1.34 surpassing the estimated $0.17 by +688.24%, while revenue for the quarter reached $192.18m , beating expectations by +124.18%.
Earnings released on 11 Nov 2021
EPS came in at -$0.34 falling short of the estimated -$0.05 by -580.00%, while revenue for the quarter reached $32.81m , missing expectations by -76.85%.
Earnings released on 12 Aug 2021
EPS came in at $0.02 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $60.39m , meeting expectations.
AVIR Stock Performance
Access detailed AVIR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
